Arvinas Potential Parkinson's Treatment Shows Positive Data In Human Study

Core Insights - Arvinas, Inc. has presented first-in-human data for its experimental Parkinson's disease treatment, ARV-102, at the 2025 International Conference on Alzheimer's and Parkinson's Diseases [1] Group 1: Clinical Trial Details - The Phase 1 trial included single ascending dose (SAD) cohorts ranging from 10 mg to 200 mg and multiple ascending dose (MAD) cohorts from 10 mg to 80 mg in healthy volunteers [2] - ARV-102, a PROteolysis TArgeting Chimera (PROTAC) LRRK2 degrader, showed a substantial reduction of LRRK2 in cerebrospinal fluid (CSF) [2] - A single oral dose of at least 60 mg ARV-102 resulted in over 50% reduction of LRRK2 protein in CSF and more than 90% reduction in peripheral blood mononuclear cells [3] Group 2: Safety and Tolerability - The trial demonstrated an encouraging safety and tolerability profile, with the most common treatment-related issues being headaches (17.1%) and fatigue (8.6%), although fatigue was more prevalent among placebo recipients (25%) [4] - Early data suggest that ARV-102 was well tolerated among the 47 volunteers across all SAD dose levels [4] Group 3: Future Plans and Market Reaction - In Q4 2024, Arvinas initiated dosing in the SAD cohort of the Phase 1 clinical trial with ARV-102 in patients with Parkinson's disease [5] - The company anticipates completing enrollment and presenting initial data from the ongoing SAD cohort in patients with Parkinson's disease, as well as initiating the MAD cohort in 2025 [5] - Following the announcement, ARVN stock experienced a decline of 4.93%, trading at $6.56 [5]